Zaire ebolavirus glycoprotein GP1,2 (EBOV GP) (EBOV GP)

The Zaire ebolavirus glycoprotein GP1,2 (EBOV GP) is the primary surface protein of the Ebola virus and is essential for the viral life cycle, specifically mediating attachment, endocytosis, and membrane fusion with host cells (UniProt P87666). It is expressed as a trimeric spike consisting of disulfide-linked GP1 and GP2 subunits; GP1 is responsible for receptor binding (notably to NPC1 in the endolysosome), while GP2 facilitates the fusion of viral and host membranes (PubMed: 30540981). The odesivimab epitope is located within the glycan cap of the GP1 subunit, a region that shields the receptor-binding domain (FDA Inmazeb Label). Odesivimab is a human monoclonal antibody that binds this epitope to neutralize the virus, and it is a key component of the FDA-approved triple-antibody combination therapy Inmazeb (REGN-EB3) (NIH: NCT03719586). By targeting multiple non-overlapping epitopes on the GP1,2 complex, therapies like Inmazeb provide high efficacy against Zaire ebolavirus and reduce the risk of treatment failure due to viral mutations (PubMed: 31774950). This specific epitope targeting allows for potent neutralization and contributes to the overall survival benefit observed in clinical trials during Ebola outbreaks.

Other names

Ebola virus glycoproteinGP1,2Envelope glycoproteinSpike proteinGP

Odesivimab is a neutralizing monoclonal antibody that binds to the glycan cap region of the GP1 subunit of the Zaire ebolavirus glycoprotein (FDA Inmazeb Label). This binding prevents the virus from interacting effectively with host cell receptors and inhibits the subsequent fusion process required for viral entry into the cytoplasm (PubMed: 32267501). As part of the Inmazeb cocktail, it works synergistically with other antibodies to neutralize the virion and potentially trigger Fc-mediated effector functions to clear infected cells (PubMed: 31774950).